STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARWR
  4. [ARS] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing

[ARS] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - ARROWHEAD PHARMACEUTICALS, INC.

ARS Filing - ARROWHEAD PHARMACEUTICALS, INC.

This filing is available as a PDF document.

Filing Type: ARS

Company: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Acceptance Date: 2026-01-26T18:52:18.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Stock ARWR logo
Arrowhead Pharma

NASDAQ:ARWR

ARWR Rankings

#1012 Ranked by Market Cap
N/A Ranked by Dividends

ARWR Latest News

Jan 27, 2026
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Jan 20, 2026
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Jan 7, 2026
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Jan 7, 2026
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Jan 6, 2026
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

ARWR Latest SEC Filings

Jan 26, 2026
[DEF 14A] ARROWHEAD PHARMACEUTICALS, INC. Definitive Proxy Statement
Jan 21, 2026
[SCHEDULE 13G/A] ARROWHEAD PHARMACEUTICALS, INC. Amended Passive Investment Disclosure
Jan 6, 2026
[8-K] ARROWHEAD PHARMACEUTICALS, INC. Reports Material Event
Jan 8, 2026
[Form 4] ARROWHEAD PHARMACEUTICALS, INC. Insider Trading Activity
Jan 8, 2026
[Form 4] ARROWHEAD PHARMACEUTICALS, INC. Insider Trading Activity

ARWR Stock Data

9.32B
131.15M
4.43%
77.49%
9.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA